AstraZeneca Plc (LON:AZN) (NYSE:AZN), a global, science-led biopharmaceutical company, reported on Tuesday that as on 30 April 2018, its issued share capital with voting rights was 1,266,613,555 ordinary shares of USD0.25.
Also, no shares are held in treasury.
Accordingly, the total number of voting rights in AstraZeneca is 1,266,613,555.
According to the company, this figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in AstraZeneca under the UK Financial Conduct Authority's Disclosure and Transparency Rules.
AstraZeneca focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The company also is selectively active in the areas of autoimmunity, neuroscience and infection.
Pfizer reports positive Phase 3 data for ABRYSVO in adults at risk for RSV disease
D3 Bio announces Series A+ Round completion to advance innovative oncology pipeline
Dizal's sunvozertinib receives US FDA Breakthrough Therapy Designation
Merck launches Phase 3 trial of MK-1084 and KEYTRUDA combination in metastatic NSCLC
Trevi Therapeutics names new vice president of Clinical Development
Personalis validates NeXT Personal test for ultra-sensitive MRD detection
Merck reports lung cancer trial failed to meet endpoints
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib